We use cookies to personalize our website and to analyze web traffic to improve the user experience. You may decline these cookies although certain areas of the site may not function without them. Please refer to our privacy policy for more information.

Skip to main content

The Jackson Laboratory

Home

Recent Searches

Share this Post

Share on facebook
Share on twitter
Share on linkedin
Share on email

Home
JAX at SITC 2023
In Vivo Evaluation of Bispecific T-Cell Engager Efficacy and Safety

In Vivo Evaluation of Bispecific T-Cell Engager Efficacy and Safety

Published Date March 24, 2023

Download PDF

Previous Flipbook

Syngeneic Tumor Studies
Next Flipbook

Onco-Hu Studies

Other content in this Stream

over 1 year ago
SITC 2023 Comparison of Blinatumomab and Biosimilar CD19xCD3 BiTE responses in PBMC-Humanized Mice Used as a Preclinical Lymphoma Mouse Mode

Read Flipbook
over 1 year ago
SITC 2023 PBMC Humanized Mouse Model with Clinical Relevance in Assessing the Safety Profile of 4-1BB Agonist, Urelumab, in 5 Donors

Read Flipbook
almost 5 years ago
Oncology - Preclinical Models and Services

Read Flipbook
over 2 years ago
Model Generation Services

Our team of subject matter experts will design your new mouse model based on your research goals.

Read Flipbook
over 2 years ago
JAX Consulting Advisory Services

Read Flipbook
almost 2 years ago
FcRn model platform

The FcRn platform from The Jackson Laboratory mimics specific aspects of the human IgG physiology providing the ideal model platform to assess the pharmacokinetics (PK) of therapeutic antibody candida

Watch Video
almost 3 years ago
Evidence-based selection of the starting dose in first-in-human clinical trials using humanized mouse models

The dose selection for first-in-human (FIH) clinical trials relies on data obtained by a combination of in vitro and in vivo studies designed to evaluate the efficacy, toxicity, and stability of...

Learn More
almost 3 years ago
Achieving Relevant Preclinical Characterization of CAR T Cell Therapies

This whitepaper examines the constraints and challenges inherent in each CAR T study type and how to overcome them with in vivo studies using fully humanized mouse models.

Read Flipbook
over 1 year ago
A MHC Class I & II Deficient Platform Humanized with PBMCs

JAX NSG-MHC I/II KO mice readily engraft tumors and human PBMCs, have delayed GvHD, and deliver translationally-relevant results for various research applications.

Read Flipbook
about 3 years ago
A New Way to Study Cytokine Release Syndrome

In vivo CRS assays have the potential to simultaneously derisk and accelerate the process of bringing successful therapies to the patients who need them most.

Read Flipbook
12 months ago
Humanized NSG Mouse Models

CD34 and PBMC humanized NSG mice are powerful preclinical models for studying the actions of immuno-modulators, either alone or in combination with other treatments.

Read Flipbook
almost 5 years ago
Syngeneic Tumor Studies

Read Flipbook
almost 2 years ago
Onco-Hu Studies

Read Flipbook

Return to Home